Efficacy and safety of pegylated (40‐kd) interferon α‐2a compared with interferon α‐2a in noncirrhotic patients with chronic hepatitis C
K. Rajender Reddy, Teresa L. Wright, Paul J. Pockros, Mitchell Shiffman, Gregory Everson, Robert Reindollar, Michael W. Fried, Preston P. Purdum, Donald Jensen, Coleman Smith, William M. Lee, Thomas D. Boyer, Amy Lin, Simon Pedder, Jean DePamphilis – 30 December 2003 – Administration of interferon (IFN) 3 times weekly in patients with chronic hepatitis C (CHC) is associated with low sustained responses, which may be, in part, related to this regimen's inability to maintain IFN concentrations sufficient to suppress viral replication.